Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies (NCT07486713)
A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib
🩺 Plain-English Summary (8th-Grade Level)
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Who can join: Review the eligibility criteria below.
Location: UCI Irvine Health — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- UCI Irvine Health — Orange, California
- New York Presbyterian Hospital-Columbia University Medical Center — New York, New York
📞 Contact the Study Coordinator
Phone: (650) 624-1100
Email: kpatel@rigel.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML (Acute Myeloid Leukemia)
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients — Duarte, California
- A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML — Grand Rapids, Michigan
- A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) — Camden, New Jersey
Explore by condition: All AML (Acute Myeloid Leukemia) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.